A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study
KCE Reports 231 (2014)
How to refer to this report
Hanquet Germaine, Christensen Hannah, Agnew Emily, Trotter Caroline, Robays Jo, Dubois Cécile, Devriese Stephan, Van De Sande Stefaan, Thiry Nancy. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study. Health Technology Assessment (HTA). Brussels. Belgian Health Care Knowledge Centre (KCE). 2014. KCE Reports 231. DOI: 10.57598/R231C.